Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings

Table 3 Significant GeneGo biological networks for proteins that met a FDR <0.05

Network number	Name	P-value	Network objects	Objects in the network*
1	Blood coagulation	1.66 e-6	7/83	UP: F12, F9, F10, PROZ, SERPING1, MST1
				DOWN: MMP2
2	Complement system	1.57 e-4	5/73	UP: SERPING1, C2 (C2a, C2b)
				DOWN: MBL2
3	Kallikrein-kinin system	2.84 e-4	7/183	UP: PLG, SERPING1, F9, F10, F12, HABP2
4	Cell adhesion, cell matrix interactions	6.34 e-4	7/209	UP: VTN, TGFBI, HABP2, LGALS3BP, LGALS1
				DOWN: MMP2, COL1A1
5	Platelet-endothelium-	1.42 e-3	6/175	UP: PLG, F12, F10, SERPING1, VTN
	leukocyte interactions			DOWN: MMP2
6	Ossification	4.34 e-3	5/152	UP: INHBE, IGFBP4, IGFBP1-IGFBP6
				DOWN: IGF1, TLL1
7	Cell proliferation	5.4 e-3	5/160	UP: IGFBP1, IGFBP4, IGFBP6
				DOWN: IGF1, MMP2
8	Protein C signaling	6.05 e-3	4/103	UP: PLG, F9, F10
				DOWN: EDG3

*UP and DOWN refer to up-regulated and down-regulated, respectively. C2, complement c2; LGALS3BP, galectin-3-binding protein; MBL2, mannose-binding protein C; NOTCH, neurogenic locus notch homolog protein 2; TGFBI, transforming growth factor-beta-induced protein ig-h3.

ISSN: 1756-994X